Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synchronous Gefitinib and Chemotherapy in Adjuvant EGFR-Mutant Lung Adenocarcinoma
NCT02518802Phase 3Unknown
- Sponsor
- Tangdu Hospital
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gefitinib in lung adenocarcinoma (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Disease Free Survival at 5 years. Status: unknown.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02518802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518802.